Concepedia

Publication | Closed Access

Predictors of response to Infliximab in children with luminal Crohn's disease

29

Citations

30

References

2014

Year

Abstract

The cumulative probability of durable response to IFX in luminal CD was 83%, 74% and 70% after 1, 2, and 3years on IFX maintenance therapy.

References

YearCitations

Page 1